Adimab Provides 2022 Update on Clinical Pipeline
This brings the total number of Adimab partner programs that have entered the clinic to 62.
- This brings the total number of Adimab partner programs that have entered the clinic to 62.
- Partners have recently filed for BLA approval on three additional programs and another three programs are currently in pivotal trials.
- “Over the last five years alone, partners have initiated clinical trials for 52 new programs.
- Bispecifics and T-cell engagers: Adimab has extensive bispecific and multispecific capabilities, including common light chain and fragment-based discovery and engineering.